Cardiovascular Drugs and Therapy最新文献

{"title":"Anticoagulation Therapy in VTE: Is a Lower Dose the Safer Choice?","authors":"Muhammad Zubair","doi":"10.1007/s10557-025-07733-x","DOIUrl":"https://doi.org/10.1007/s10557-025-07733-x","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Macrophage CBX4 Potentiates Atherosclerosis by its SUMO E3 Ligase Activity.","authors":"Zhenyu Zhao, Senping Xu, Jianying Ma, Zhaoshan Zhang, Sijia Liang, Jiawei Guo","doi":"10.1007/s10557-025-07724-y","DOIUrl":"https://doi.org/10.1007/s10557-025-07724-y","url":null,"abstract":"<p><strong>Purpose: </strong>Atherosclerosis (AS) is the leading cause of cardiovascular disease and mortality worldwide. Despite extensive research, there remains an urgent need for novel therapeutic strategies. By integrating genomic data from the Gene Expression Omnibus (GEO) with human atherosclerotic tissues, we identified enrichment of sumoylation pathways in AS, with chromobox 4 (CBX4), a SUMO E3 ligase, being significantly upregulated. This study aims to investigate the role of CBX4 in macrophages during atherosclerosis progression and its potential molecular mechanisms.</p><p><strong>Methods: </strong>We analyzed gene expression profiles from human atherosclerotic segments to identify differentially expressed pathways. High-fat diet (HFD)-challenged apolipoprotein E-deficient (ApoE^-/-) mice were used to examine CBX4 expression in macrophages. The impact of CBX4 on atherosclerosis was assessed using macrophage-specific CBX4 knockdown and overexpression models. Mechanistically, we evaluated the interaction between CBX4 and hypoxia-inducible factor 1-alpha (HIF-1α) and its effect on sumoylation and transcriptional activity.</p><p><strong>Results: </strong>CBX4 expression was elevated in macrophages from atherosclerotic lesions of HFD-fed ApoE^-/- mice. Macrophage-specific CBX4 knockdown significantly alleviated HFD-induced AS, whereas CBX4 overexpression exacerbated atherosclerotic progression. Mechanistically, CBX4 directly interacted with HIF-1α and promoted its sumoylation, leading to increased HIF-1α transcriptional activity, which may contribute to AS development.</p><p><strong>Conclusions: </strong>Our findings highlight CBX4-promoted SUMOylation of HIF-1α exacerbates AS progression. Targeting CBX4 may represent a promising therapeutic strategy for mitigating atherosclerosis progression.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombocytopenia and Antiphospholipid Syndrome.","authors":"Philip Murphy","doi":"10.1007/s10557-025-07730-0","DOIUrl":"https://doi.org/10.1007/s10557-025-07730-0","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary Artery Bypass Grafting With or Without Concomitant Surgical Ventricular Reconstruction in Ischemic Cardiomyopathy Patients.","authors":"Jianbo Liao, Zhuoming Zhou, Yi Zhang, Zhilin Miao, Gang Li, Hanri Xiao, Qiushi Ren, Bohao Jian, Zhongkai Wu, Mengya Liang","doi":"10.1007/s10557-025-07728-8","DOIUrl":"https://doi.org/10.1007/s10557-025-07728-8","url":null,"abstract":"<p><strong>Purpose: </strong>The present study aims to compare the long-term outcomes of surgical ventricular reconstruction (SVR) combined with coronary artery bypass grafting (CABG) versus CABG alone in patients with ischemic cardiomyopathy (ICM).</p><p><strong>Methods: </strong>A systematic literature search was conducted in PubMed, Embase, Scopus, Cochrane Library, and Web of Science until November 2024. Studies comparing SVR + CABG and CABG in patients with ischemic cardiomyopathy (left ventricular ejection fraction less than 40%) were included. The primary outcome included long-term mortality, and the secondary outcomes included hospital mortality, rehospitalization for cardiac causes, and other cardiac function indicators.</p><p><strong>Results: </strong>Twelve studies with a total of 3188 patients were included, with 1629 undergoing SVR + CABG and 1559 undergoing CABG. Patients who underwent SVR + CABG had a higher survival rate (HR 0.82; 95% CI, 0.69-0.96; I² = 4%; P = 0.01) and a more significant postoperative left ventricular end-systolic volume index (ESVI) reduction (MD 15.53; 95% CI, 6.41-24.65; I² = 93%; P = 0.01). In the subgroup analysis, the Dor (endoventricular circular patch plasty) surgery provided additional survival benefits compared with CABG (HR 0.83; 95% CI, 0.70-0.97; I² = 9%; P = 0.02). The reconstructed Kaplan-Meier curves show that the survival rates in the SVR + CABG, Dor, Non-Dor, Mannequin-free, Mannequin, and CABG groups were 81.13%, 82.02%, 76.38%, 83.23%, 69.40%, and 71.42% at 60 months, respectively.</p><p><strong>Conclusions: </strong>Compared with CABG, SVR + CABG is associated with higher survival, a more significant reduction in ESVI, fewer rehospitalizations for cardiac causes, and more patients gaining postoperative New York Heart Association class improvement.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can Inclisiran Emerge in the Crowded Lipid-Lowering Therapy Landscape?","authors":"Chunyu Wu, Renlin Yin","doi":"10.1007/s10557-025-07731-z","DOIUrl":"https://doi.org/10.1007/s10557-025-07731-z","url":null,"abstract":"","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sotagliflozin: Two Birds with One Stone?","authors":"Juan Antonio Requena-Ibáñez, Kristine Mørk Kindberg, Carlos G Santos-Gallego, M Urooj Zafar, Juan J Badimon","doi":"10.1007/s10557-025-07723-z","DOIUrl":"https://doi.org/10.1007/s10557-025-07723-z","url":null,"abstract":"<p><strong>Purpose: </strong>Sodium-glucose cotransporter 2 inhibitors (SGLT2i), initially developed as antidiabetic agents, have become a cornerstone in the treatment of heart failure (HF) due to their well-established cardio-renal benefits. Clinical trials with SGLT2i have shown a reduction in major adverse cardiovascular events (MACE) across a broad range of patients with no effect on atherothrombotic cardiovascular events such as myocardial infarction (MI) or stroke. On the other hand, sotagliflozin, the first of a new class of dual SLGT1-2 inhibitor (SGLT1-2i), reduces MACE, with independent reductions in MI and stroke, an effect not seen with SGLT2 inhibition alone.</p><p><strong>Method: </strong>A comprehensive literature review was conducted using PubMed and Scopus, focusing on publications from the last 5 years. Articles were selected based on relevance, methodological rigor, and citation impact.</p><p><strong>Results: </strong>SGLT1 and SGLT2 work complimentarily in urinary glucose reabsorption, while SGlT1 also regulates dietary glucose in the intestine. However, its function in other organs remains undefined. SGLT1 is overexpressed in the failing heart and has been associated with increased oxidative stress, cardiomyocyte hypertrophy, and fibrosis. Additionally, SGLT1 also plays an important role in platelet activation and thrombus formation. Experimental studies suggest that sotagliflozin, by inhibiting SGLT1, reverses the metabolic derangements associated with SGLT1 overexpression.</p><p><strong>Conclusion: </strong>These observations suggest that dual SGLT1-2 inhibition may offer additional benefits over single SGLT2-i. Further comparative and mechanistic studies are required to understand and differentiate the clinical impact of SGLT2i vs. SGLT1-2i, particularly in non-diabetic HF patients.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vagus Nerve Stimulation by Focused Ultrasound Attenuates Acute Myocardial Ischemia/Reperfusion Injury Predominantly Through Cholinergic Anti-inflammatory Pathway.","authors":"Qian Zhang, Qianyun Cai, Shenrong Zhong, Qin Li, Weibao Qiu, Juefei Wu","doi":"10.1007/s10557-025-07718-w","DOIUrl":"https://doi.org/10.1007/s10557-025-07718-w","url":null,"abstract":"<p><strong>Purpose: </strong>This study investigates the cardioprotective effects of focused ultrasound stimulation (FUS) as a novel, noninvasive intervention for mitigating acute myocardial ischemia/reperfusion (I/R) injury.</p><p><strong>Methods: </strong>In rat I/R models (30-min left anterior descending coronary artery (LAD) occlusion followed by 2-/24-h reperfusion), FUS was applied to the right cervical vagus nerve during early reperfusion (10-60 min post-reperfusion). The effects of FUS were assessed by analyzing inflammatory markers, arrhythmia incidence, pathological changes, echocardiographic parameters, pro-/anti-oxidative biomarkers, myocardial fibrosis, and infarct size. To elucidate the underlying mechanism, vagotomy and atropine administration were performed.</p><p><strong>Results: </strong>FUS significantly reduced heart rate and inflammation in the 2-h reperfusion model. Compared to the I/R group, the I/R + FUS group exhibited markedly decreased premature ventricular contractions (221.00 ± 166.93 vs 83.11 ± 34.08, p < 0.05), ventricular tachycardia and ventricular fibrillation (16.67 ± 10.68 vs. 3.67 ± 3.24, p < 0.01), and arrhythmia scores during reperfusion (2.44 ± 1.13 vs. 0.67 ± 0.50, p < 0.01). In the 24-h reperfusion model, FUS significantly reduced myocardial fibrosis and infarct size (infarct size/area at risk 49.60 ± 9.17% vs. 20.73 ± 4.91%, p < 0.001) and preserved left ventricular ejection fraction (35.68 ± 9.95% vs 56.73 ± 2.64%, p < 0.001). The protective effects of FUS were abolished by vagotomy or atropine, suggesting the cholinergic anti-inflammatory pathway as a potential mechanism.</p><p><strong>Conclusion: </strong>Targeted FUS neuromodulation exerts acute and sustained cardioprotection against I/R injury primarily through cholinergic anti-inflammatory mechanisms, offering a safer and more accessible alternative to traditional treatments.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Midodrine Utilization in Patients with Cancer and Heart Failure.","authors":"Jorge A Irizarry-Caro, Juhee Song, Chase Miller, Shyam Desai, James Going, Jose Fossas-Espinosa, Mariya M Fatakdawala, Abdelrahman Ali, Cezar Iliescu, Nicolas Palaskas, Anita Deswal, Efstratios Koutroumpakis","doi":"10.1007/s10557-024-07546-4","DOIUrl":"10.1007/s10557-024-07546-4","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this study was to evaluate safety and cardiovascular outcomes as well as overall survival of cancer patients with concomitant heart failure (HF) treated with midodrine for hypotension.</p><p><strong>Methods: </strong>Adult patients diagnosed with cancer and HF who were treated with midodrine at a tertiary cancer center from 03/2013 to 08/2021 were identified. Demographic and clinical parameters were collected retrospectively.</p><p><strong>Results: </strong>A total of 85 patients were included with a median age of 68 years (IQR: 60, 74; 33% female and 85% White). Of those, 31% had HFpEF (EF ≥ 50%), 42% HF with mildly reduced EF (HFmrEF; EF 41-49%), and 27% HFrEF (EF ≤ 40%). The most common indication for midodrine use was orthostatic hypotension (49%). Midodrine was continued for at least one month in 57% of the patients. Supine hypertension was the only side effect reported in 6% of patients. No statistically significant changes in NYHA class, guideline-directed medical therapy, cardiac biomarkers (NT-proBNP or troponin T), echocardiographic findings or cardiovascular hospitalizations were observed between patients who continued treatment with midodrine compared to those who stopped using midodrine over a median follow-up of 38 months. In the multivariable cox regression analysis, continuation of midodrine, compared to discontinuation, and use of midodrine for orthostatic hypotension, as opposed to other causes of hypotension, were not associated with an increased risk of mortality (HR 0.41, 95% CI 0.24-0.69, p < .0001; HR 0.34, 95% CI 0.18-0.64, p < .001, respectively). In contrast, elevated creatinine (> 1.3 for males and > 1.1 for females) was associated with an increased risk of mortality (HR 1.83, 95% CI 1.07-3.14). LVEF was not significantly associated with lower or higher risk of mortality.</p><p><strong>Conclusions: </strong>In our study, midodrine use in patients with cancer and HF was not associated with significant adverse effects, worse cardiovascular outcomes, or increased risk of mortality. Larger, prospective studies are needed to confirm these findings.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"553-562"},"PeriodicalIF":3.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Kidney Injury in Different Anticoagulation Strategies: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data.","authors":"Qiuyu Xu, Gang Chen, Sanxi Ai, Ke Zheng, Bin Zhao, Xuemei Li","doi":"10.1007/s10557-024-07558-0","DOIUrl":"10.1007/s10557-024-07558-0","url":null,"abstract":"<p><strong>Purpose: </strong>Acute kidney injury (AKI) following anticoagulant application has received growing attention as a significant emerging complication of anticoagulation. Nevertheless, there remains a lack of real-world studies to compare the incidence, clinical features, and prognosis of AKI across different anticoagulant regimens.</p><p><strong>Methods: </strong>Disproportionality analysis and Bayesian analysis were used to identify suspected AKI cases after different anticoagulant use within the Food and Drug Administration's Adverse Event Reporting System from January 2004 to March 2023. The time to onset, fatality, and hospitalization rates of anticoagulant-associated AKI were also investigated.</p><p><strong>Results: </strong>We identified 9313 anticoagulant-associated AKIs, which appeared to influence mostly patients over 65 years old (65.37%). Lepirudin displayed a stronger AKI association than others, based on the highest reporting odds ratio (ROR = 6.66, 95% CI = 3.97-11.18), proportional reporting ratio (PRR = 6.08, χ2 = 69.12), and empirical Bayes geometric mean (EBGM = 6.08, the lower 90% one-sided CI = 3.95). Warfarin showed the slightest association with AKI in oral anticoagulants, lower than any direct oral anticoagulants excluding apixaban. Edoxaban exhibited the highest potential renal risk among direct oral anticoagulants, with an ROR of 3.32 (95% CI = 2.95-3.72). The median time to AKI onset was 36 (IQR 7-205) days following the initiation of anticoagulation therapy, and most AKI cases occurred within the first month.</p><p><strong>Conclusion: </strong>Particular attention should be directed toward monitoring renal function in individuals receiving anticoagulants, including warfarin and direct oral anticoagulants, as well as other anticoagulant agents. This diligence is particularly imperative within the first month after anticoagulant administration for individuals with a tendency for AKI.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"563-572"},"PeriodicalIF":3.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Integrated Network Pharmacology and RNA-seq Approach for Exploring the Protective Effect of Andrographolide in Doxorubicin-Induced Cardiotoxicity.","authors":"Sa Liu, Jiaqin Liu, Nan Su, Shanshan Wei, Ning Xie, Xiangyun Li, Suifen Xie, Jian Liu, Bikui Zhang, Wenqun Li, Shengyu Tan","doi":"10.1007/s10557-024-07555-3","DOIUrl":"10.1007/s10557-024-07555-3","url":null,"abstract":"<p><strong>Purpose: </strong>Doxorubicin (Dox) is clinically limited due to its dose-dependent cardiotoxicity. Andrographolide (Andro) has been confirmed to exert cardiovascular protective activities. This study aimed to investigate protective effects of Andro in Dox-induced cardiotoxicity (DIC).</p><p><strong>Methods: </strong>The cardiotoxicity models were induced by Dox in vitro and in vivo. The viability and apoptosis of H9c2 cells and the myocardial function of c57BL/6 mice were accessed with and without Andro pretreatment. Network pharmacology and RNA-seq were employed to explore the mechanism of Andro in DIC. The protein levels of Bax, Bcl2, NLRP3, Caspase-1 p20, and IL-1β were qualified as well.</p><p><strong>Results: </strong>In vitro, Dox facilitated the downregulation of cell viability and upregulation of cell apoptosis, after Andro pretreatment, the above symptoms were remarkably reversed. In vivo, Andro could alleviate Dox-induced cardiac dysfunction and apoptosis, manifesting elevation of LVPWs, LVPWd, EF% and FS%, suppression of CK, CK-MB, c-Tnl and LDH, and inhibition of TUNEL-positive cells. Using network pharmacology, we collected and visualized 108 co-targets of Andro and DIC, which were associated with apoptosis, PI3K-AKT signaling pathway, and others. RNA-seq identified 276 differentially expressed genes, which were enriched in response to oxidative stress, protein phosphorylation, and others. Both network pharmacology and RNA-seq analysis identified Tap1 and Timp1 as key targets of Andro in DIC. RT-QPCR validation confirmed that the mRNA levels of Tap1 and Timp1 were consistent with the sequenced results. Moreover, the high expression of NLRP3, Caspase-1 p20, and IL-1β in the Dox group was reduced by Andro.</p><p><strong>Conclusions: </strong>Andro could attenuate DIC through suppression of Tap1 and Timp1 and inhibition of NLRP3 inflammasome activation, serving as a promising cardioprotective drug.</p>","PeriodicalId":9557,"journal":{"name":"Cardiovascular Drugs and Therapy","volume":" ","pages":"517-531"},"PeriodicalIF":3.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139943900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}